Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma

Phase 2 Recruiting 30 enrolled University of California, San Diego Bristol-Myers Squibb · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase 2 clinical trial with a 2:1 randomization comparing neoadjuvant Nivolumab + Relatlimab (Opdualag) vs neoadjuvant Nivolumab in patients with resectable high risk basal cell carcinoma (HR BCC)

Timeline

Start: 2025-08-21
Primary completion: 2028-05
Completion: 2028-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nivolumab	Monoclonal antibody	480 mg	Intravenous
Subject	Relatlimab	Monoclonal antibody	160 mg	Intravenous

Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma

Summary

Timeline

Drugs

Indications